D-0323-2020 Class III Terminated
FDA drug recall D-0323-2020 was initiated by Sato Pharmaceutical Inc. on Oct 1, 2019 and is designated Class III. Reason for recall: Subpotent Drug The recall status is terminated (terminated Aug 18, 2020). Affected quantity: 210,744 units.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 20, 2019
- Initiation Date
- Oct 1, 2019
- Termination Date
- Aug 18, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 210,744 units
Product description
Motion Sickness (meclizine hydrochloride) 25 mg tablets, 12-count box, Distributed by Sato Pharmaceutical INC. 20695 S. Western Ave., Suite 240 Torrence, CA 90501, NDC 59779-534-01. UPC 050428345535
Reason for recall
Subpotent Drug
Distribution pattern
Nationwide within the United States, Guam and Saipan
Code information
Lot #: TXWP, TXTP, Exp. date Jul 2020; AXTZ, Exp. date Mar 2021; AXNP, Exp. date Jul 2021; AXBC, Exp. date Oct 2021; ZXWW, Exp. date Dec 2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0323-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026